FDA grants orphan drug designation to myelodysplastic syndrome drug

10/6/2013 | Pharmaceutical Business Review Online

Cornerstone Pharmaceuticals announced that CPI-613, its myelodysplastic syndrome drug, has been given orphan drug status by the FDA. The altered energy metabolism directed drug candidate is in Phase I, I/II and Phase II trials focused on hematologic malignancies and solid tumors.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI